Market capitalization | €982.02m |
Enterprise Value | €840.17m |
P/E (TTM) P/E ratio | 20.83 |
EV/FCF (TTM) EV/FCF | 11.07 |
EV/Sales (TTM) EV/Sales | 1.56 |
P/S ratio (TTM) P/S ratio | 1.83 |
P/B ratio (TTM) P/B ratio | 1.81 |
Dividend yield | 1.02% |
Last dividend (FY23) | €0.85 |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
6 Analysts have issued a Vetoquinol forecast:
6 Analysts have issued a Vetoquinol forecast:
Jun '24 |
+/-
%
|
||
Revenue | 537 537 |
2%
2%
|
|
Gross Profit | 69 69 |
14%
14%
|
|
EBITDA | 94 94 |
10%
10%
|
EBIT (Operating Income) EBIT | 62 62 |
16%
16%
|
Net Profit | 47 47 |
20%
20%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Vétoquinol SA operates as a global animal health company. It supplies drugs and nonmedicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets. The firm designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region. It also manufactures antibiotic, anti-inflammatory, cardiology, and nephrology drugs. The company was founded by Joseph Frechin in 1933 and is headquartered in Lure, France.
Head office | France |
CEO | Matthieu Frechin |
Employees | 2,483 |
Founded | 1962 |
Website | www.vetoquinol.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.